Indexed with PubMed and Science Citation Index (E) 
Users online: 1352 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
    Next article
    Previous article
    Table of Contents

    Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
  Related articles
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded393    
    Comments [Add]    
    Cited by others 4    

Recommend this journal


Year : 2003  |  Volume : 69  |  Issue : 5  |  Page : 334--337

Treatment of pemphigus with intravenous pulse cyclophosphamide

Department of Dermatology, Venereology and Leprosy, B. J. Medical College and Sassoon General Hospitals, Pune - 411001, India

Correspondence Address:
N R Gokhale
39/30, Smruti Lane No. 9, Prabhat Road, Pune - 411004
Login to access the Email id

Source of Support: None, Conflict of Interest: None

PMID: 17642931

Rights and PermissionsRights and Permissions

Background: The complications associated with the use of systemic corticosteroid therapy have prompted a search for alternative agents. However, these agents are themselves associated with increased risk of myelosuppression or malignancy. Methods: The present study included twenty patients with recalcitrant pemphigus or steroid induced side effects who were treated with intravenous cyclophosphamide pulse therapy. Results: Out of 18 patients who completed the study, 14 showed good to excellent response. Thirteen were able to decrease their daily dose of steroid to 5-10 mg prednisolone while one could stop steroids altogether. Most patients did not experience serious side effects. Discussion: Thus intravenous pulse cyclophosphamide is a promising form of therapy in pemphigus either recalcitrant or intolerant to steroid therapy. The decreased total cumulative dose of cyclophosphamide with intravenous therapy as compared to oral therapy may reduce the incidence of secondary malignancy.


Print this article     Email this article

Online since 15th March '04
Published by Wolters Kluwer - Medknow